Management of breast cancer--Part I
| Autor: | Alison L Jones, Nicholas C. Turner |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Clinical Review
Pathology medicine.medical_specialty medicine.medical_treatment Genes BRCA2 Mammary gland Genes BRCA1 Antineoplastic Agents Breast Neoplasms Targeted therapy Breast cancer Risk Factors Trastuzumab medicine Humans Minimally Invasive Surgical Procedures skin and connective tissue diseases Germ-Line Mutation General Environmental Science business.industry General Engineering Cancer General Medicine medicine.disease Magnetic Resonance Imaging Radiation therapy medicine.anatomical_structure Cancer research General Earth and Planetary Sciences Female Radiotherapy Adjuvant Breast disease business Tamoxifen Mammography medicine.drug |
| Zdroj: | BMJ. 337:a421-a421 |
| ISSN: | 1468-5833 0959-8138 |
| Popis: | Summary points Breast cancer comprises a spectrum of related but different cancer subtypes, which have different causal genetic changes, may follow different clinical courses, and require different treatments tailored to the phenotype (fig 1⇓). Here, in this second part of our review on breast cancer, we discuss the recent advances in the systemic therapy of breast cancer, and the current drive to individualise treatment according to patient and tumour factors. Fig 1 Diagram showing how breast cancer subtypes influence treatment. Breast tumours at the molecular level cluster into three main subtypes of cancer: luminal-type (with subtypes A and B), HER2, and basal-like. Luminal-type breast cancers express the oestrogen receptor (ER) and related genes and can be targeted with hormonal therapies; the less aggressive (subtype A) cancers may be less sensitive to chemotherapy than the more aggressive (type B) cancers. HER2 breast cancers, characterised by overexpression of the growth factor receptor HER2 with amplification of the HER2 gene, are aggressive with a poor prognosis. HER2 positive cancers can be targeted with the monoclonal antibody trastuzumab and also may be highly chemotherapy sensitive. About half of HER2 positive cancers express the oestrogen receptor. Basal-like cancers do not usually express either of the hormone receptors (oestrogen or progesterone) or overexpress the growth factor receptor HER2, a phenotype named “triple negative.” Basal-like cancers are highly proliferative and have a poor prognosis, although many are highly sensitive to chemotherapy. There is no subtype specific targeted therapy. (The clustering of genome-wide gene expression analysis is adapted from … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|